학술논문
JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality.
Document Type
Article
Author
Stebbing, Justin; Sánchez Nievas, Ginés; Falcone, Marco; Youhanna, Sonia; Richardson, Peter; Ottaviani, Silvia; Shen, Joanne X.; Sommerauer, Christian; Tiseo, Giusy; Ghiadoni, Lorenzo; Virdis, Agostino; Monzani, Fabio; Rizos, Luis Romero; Forfori, Francesco; Avendaño Céspedes, Almudena; De Marco, Salvatore; Carrozzi, Laura; Lena, Fabio; Sánchez-Jurado, Pedro Manuel; Lacerenza, Leonardo Gianluca
Source
Subject
*SARS-CoV-2
*ASPARTATE aminotransferase
*ENTEROCOCCAL infections
*INTERFERON receptors
*DISEASES
*INFLAMMATION
*COVID-19
*LIFE sciences
*
*
*
*
*
*
*
Language
ISSN
2375-2548
Abstract
The article presents research report on Janus kinase inhibitors (JAK) inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality. Topics include mortality benefit in patients with moderate-severe SARS-CoV-2 pneumonia with few drug-induced adverse event; and cytokine storm and is associated with beneficial outcomes including in severely ill elderly patients, data that incentivize further randomized controlled trials.